Company / Cost of Revenue
Dexcom Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.9B
FY2025
5-year range
$646.6M / $1.9B
FY2021-FY2025
Trend
+16.6%
vs FY2024
Sector context
#31 of 113
Health Care
What the data says
At $1.9B, Dexcom's cost of revenue ranks #83 of 113 in the Health Care sector. Cost of Revenue has increased for 3 consecutive years, from $647M in FY2022 to $1.9B in FY2025.
Based on SEC 10-K filings.
$1.9B in FY2025 with a 5-year CAGR of +23.5%.
Increased from $1.3B to $1.9B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +42.2%
- 5-Year CAGR
- +23.5%
- 10-Year CAGR
- -
Sector benchmark
#83 of 113 in Health CareTop 73% of 113This company $1.9B Sector average $11.3B
▼
-83.5% below sector average
Key checks
Key Insights
- Dexcom's cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +23.5%, indicating consistent growth.
- In FY2025, cost of revenue increased 16.6% year-over-year.
- Ranks #31 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
- Strong return on equity: 26.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9B | +16.6% |
| FY2024 | $1.6B | +19.6% |
| FY2023 | $1.3B | +106.2% |
| FY2022 | $646.6M | -15.8% |
| FY2021 | $768.0M | +18.8% |
| FY2020 | $646.6M | +18.8% |
| FY2019 | $544.5M | +48.1% |
| FY2018 | $367.7M | +197.5% |
| FY2017 | $123.6M | +49.1% |
| FY2016 | $82.9M | +38.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026